Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles

https://doi.org/10.1016/S0378-5173(02)00315-0Get rights and content

Abstract

Nanoparticles formulated from biodegradable polymers such as poly (lactic acid) and poly (d,l-lactide-co-glycolide) (PLGA) are being extensively investigated as non-viral gene delivery systems due to their sustained release characteristics and biocompatibility. PLGA nanoparticles for DNA delivery are mainly formulated using an emulsion-solvent evaporation technique. However, this formulation procedure results in the formation of particles with heterogeneous size distribution. The objective of the present study was to determine the relative transfectivity of the smaller- and the larger-sized fractions of nanoparticles in cell culture. PLGA nanoparticles containing a plasmid DNA encoding luciferase protein as a marker were formulated by a multiple emulsion-solvent evaporation method (mean particle diameter=97±3 nm) and were fractionated using a membrane (pore size: 100 nm) filtration technique. The particles that passed through the membrane were designated as the smaller-sized nanoparticles (mean diameter=70±2 nm) and the fraction that was retained on the membrane as the larger-sized nanoparticles (mean diameter=202±9 nm). The smaller-sized nanoparticles showed a 27-fold higher transfection than the larger-sized nanoparticles in COS-7 cell line and a 4-fold higher transfection in HEK-293 cell line. The surface charge (zeta potential), cellular uptake, and the DNA release were almost similar for the two fractions of nanoparticles, suggesting that some other yet unknown factor(s) is responsible for the observed differences in the transfection levels. The results suggest that the particle size is an important factor, and that the smaller-sized fraction of the nanoparticle formulation predominantly contributes towards their transfection.

Introduction

Gene therapy, the introduction of an extraneous gene into a cell with the aim of replacing a lost cellular function or to introduce a new functionality, is fast becoming a reality (Rubanyi, 2001). However, achieving an efficient gene delivery into the target cell population or tissue without causing any vector-associated toxicity is critical to the success of gene therapy (Clark and Johnson, 2001). To achieve the above objective, various viral and non-viral vectors have been investigated (Kataoka and Harashima, 2001). Although viral vectors such as adenovirus, influenza virus and adeno-associated virus (Kochanek et al., 2001) are relatively more efficient in gene transfection than non-viral methods (Li and Huang, 2000), their toxicity and immunogenicity are the major concerns. Therefore, non-viral vectors such as liposomes, cationic block copolymers, polymer complexes, and micro- and nanoparticles have gained importance because they are relatively safe and are easy to formulate (Luo et al., 1999, Maheshwari et al., 2000). More recently, biodegradable nanoparticles formulated using different polymers such as chitosan (Mao et al., 2001, Roy et al., 1999), gelatin (Truong-Le et al., 1998), and other biodegradable polymers (Roy et al., 1999, Cohen et al., 2000) are being investigated as non-viral gene delivery systems because of the possibility of achieving safe and sustained gene transfection.

We have been investigating biodegradable nanoparticles formulated from poly (d,l-lactide-co-glycolide) (PLGA), an FDA approved biocompatible and biodegradable polymer, as a non-viral gene delivery system (Labhasetwar et al., 1999). Nanoparticles, because of their subcellular size, are effectively endocytosed by the cells which could result in higher cellular uptake of the entrapped DNA (Panyam et al., 2002b, Davda and Labhasetwar, 2002). Recently, we have demonstrated the rapid escape of PLGA nanoparticles from the endo-lysosomal compartment into cytoplasm, suggesting the suitability of nanoparticles as a gene delivery vector (Panyam et al., 2002b). Since the DNA is encapsulated inside the polymeric matrix, it would be protected from extracellular and intracellular nuclease degradation (Hedley et al., 1998). The DNA entrapped in nanoparticles is released slowly with the hydrolysis of the polymer matrix due to the cleavage of the ester bonds. It is hypothesized that the slow release of DNA from nanoparticles intracellularly would be effective in achieving sustained gene expression in the target tissue. Sustained and regulated gene expression is probably more important in treating certain localized disease conditions such as the cardiac and limb ischemia by inducing neovascularization in the damaged tissue using genes encoding pro-angiogenic growth factors (Richardson et al., 2001). Similarly, sustained gene expression has been shown to be effective in bone regeneration, which could be useful to repair fractured bones (Bonadio et al., 1999). Restenosis, a vasculoproliferative condition that occurs following coronary balloon angioplasty procedure, is another example of a pathological condition where sustained gene expression in the target artery could be more effective (Ohno et al., 1994, Klugherz et al., 2000).

Various formulation factors and characteristics of nanoparticles could influence the transfectivity of nanoparticles. One of the important parameters that could affect the transfectivity of nanoparticles is their size. The particle size has been an important consideration while formulating other particulate type systems such as DNA-polymer (Dauty et al., 2001) and lipid complexes (Lee et al., 2001) and liposomes (Sakurai et al., 2000). Our studies and that of others have shown that the particle size significantly affects their cellular and tissue uptake (Desai et al., 1997, Zauner et al., 2001), and in some cell lines, only the submicron size particles are taken up efficiently but not the larger size microparticles (e.g. Hepa 1-6, HepG2, and KLN 205) (Zauner et al., 2001). Nanoparticles prepared by emulsion-solvent evaporation technique using PLGA polymer usually results in the formation of nanoparticles with heterogeneous particle size distribution. We hypothesized that the transfectivity of the different sized nanoparticle fractions in the formulation could be different. Therefore, the objective of the present study was to determine the relative transfectivity of the smaller- and the larger-sized fractions of nanoparticles in cell culture.

Section snippets

Materials

PLGA (MW 143 900 Da, copolymer ratio 50:50) was purchased from Birmingham Polymers, Inc. (Birmingham, AL). Acetylated bovine serum albumin (Ac-BSA), MEM non-essential amino acid solution (100×), and polyvinyl alcohol (PVA, average MW 30 000–70 000) were purchased from Sigma Chemical Co. (St. Louis, MO). Fetal bovine serum (FBS, heat inactivated), 1× trypsin-EDTA, Dulbecco's modified essential medium (DMEM), and penicillin-streptomycin were obtained from Gibco-BRL (Grand Island, NY). African

Characterization of nanoparticles containing plasmid DNA

The unfractionated nanoparticles, when analyzed by dynamic light scattering, demonstrated a bimodal size distribution with particles in two size ranges: 95–130 nm and 330–450 nm (Fig. 1A). Following fractionation, both the fractions demonstrated unimodal particle size distribution. The fraction that passed through the membrane was designated as the smaller-sized nanoparticles and the fraction that was retained on the membrane was designated as the larger-sized nanoparticles. The smaller-sized

Conclusions

In this study, we have shown that the double-emulsion solvent evaporation technique commonly used for PLGA nanoparticle formulation results in a heterogeneous particle-size distribution and that the smaller-sized fraction of nanoparticles (<100 nm) has significantly higher transfection efficiency as compared to the larger-sized fraction of nanoparticles (>100 nm). The greater transfection of the smaller-sized fraction as compared to the larger-sized fraction of nanoparticles does not seem to be

Acknowledgements

Grant support from the Nebraska Research Initiative, Gene Therapy Program and the National Institutes of Health, the Heart, Lung and Blood Institute (HL-57234) is appreciated. S.P. is supported by a predoctoral fellowship (DAMD-17-02-1-0506) from Department of Army, the US Army Medical Research Association Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014. J.P. is supported by a predoctoral fellowship from the American Heart Association, Heartland Affiliate. We would like to thank Dr.

References (38)

  • G.M. Rubanyi

    The future of human gene therapy

    Mol. Aspects Med.

    (2001)
  • F. Sakurai et al.

    Effect of DNA/liposome mixing ratio on the physicochemical characteristics, cellular uptake and intracellular trafficking of plasmid DNA/cationic liposome complexes and subsequent gene expression

    J. Control. Release.

    (2000)
  • E. Walter et al.

    Microencapsulation of DNA using poly(dl-lactide-co-glycolide): stability issues and release characteristics

    J. Control. Release

    (1999)
  • D. Wang et al.

    Encapsulation of plasmid DNA in biodegradable poly(d,l-lactic-co-glycolic acid) microspheres as a novel approach for immunogene delivery

    J. Control. Release

    (1999)
  • M.F. Zambaux et al.

    Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method

    J. Control. Release

    (1998)
  • W. Zauner et al.

    In vitro uptake of polystyrene microspheres: effect of particle size, cell line and cell density

    J. Control. Release

    (2001)
  • D. Bergan et al.

    Gene transfer in vitro and in vivo by cationic lipids is not significantly affected by levels of supercoiling of a reporter plasmid

    Pharm. Res.

    (2000)
  • J. Bonadio et al.

    Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration

    Nat. Med.

    (1999)
  • K.R. Clark et al.

    Gene delivery of vaccines for infectious disease

    Curr. Opin. Mol. Ther.

    (2001)
  • Cited by (0)

    View full text